mid-brain progenitor cell therapy (CellCure Neurosciences)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namemid-brain progenitor cell therapy (CellCure Neurosciences)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Embryonic stem cells therapyCell and gene therapy > Cell therapy > Stem cell therapy > Neurogenic potential stem cell therapy

Mechanisms of ActionImmunomodulatorsDopamine modulatorsStem cells modulators

TargetsUpdating

Therapy Area/IndicationsParkinson DiseaseMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCellcure Neurosciences Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCellcure Neurosciences Ltd Hadasit Bio-Holdings Ltd

Active IndicationsN/A

Inactive IndicationsParkinson DiseaseMultiple Sclerosis

Other Information

ATC CodeN/A